SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF

Inclusion Criteria: * Written informed consent. * Patients aged 18 years or older. * Chronic coronary syndrome scheduled for elective isolated CABG surgery with extra corporeal circulation, or elective CABG surgery with extra corporeal circulation combined with aortic valve replacement, mitral valve surgery, and / or aortic root surgery. Exclusion Criteria: * Treatment with an SGLT2 inhibitor within 8 weeks prior to enrolment or planned treatment. * Intolerance, hypersensitivity, or other contraindications of dapagliflozin. * Type 1 diabetes mellitus. * Symptomatic hypotension or systolic blood pressure \<95 mmHg at two out of three measurements at enrolment. * Current acute decompensated heart failure or hospitalization due to decompensated heart failure \<4 weeks prior to enrolment. * Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, or hypertrophic cardiomyopathy. * Implantation or intent to implant a cardiac resynchronization device within 12 weeks prior to enrolment. * Stroke or transient ischemic attack within 12 weeks prior to enrolment. * Symptomatic bradycardia or second or third-degree atrioventricular block without pacemaker treatment. * Any condition such as, but not limited to, malignancy, with a life expectancy of \<2 years based on the investigator's clinical judgement. * Hepatic impairment (aspartate transaminase or alanine transaminase \>3 × the upper limit of normal, or total bilirubin \>2 × upper limit of normal at the time of enrolment). * Severe (estimated glomerular filtration rate \< 25 mL/min/1.73 m2), unstable, or rapidly progressing renal disease at the time of enrolment. * CABG surgery planned within one week. * Emergency surgery with hemodynamic instability. * Previous history of AF. * Women of childbearing potential (i.e., those who are fertile, following menarche and until becoming post-menopausal, unless permanently sterile\*) 1. Who are not willing to use a highly effective method of contraception\*\* judged by the investigator, from the time of signing the informed consent throughout the trial and 4 weeks thereafter, OR 2. Who have a positive pregnancy test at enrolment or randomization, OR 3. Who are breast-feeding. * Participation or recent participation in a clinical trial with an investigational medicinal product within 30 days before randomization. * Previous randomization in the STENOTYPE trial. * Previous (within 30 days) or concomitant participation in another clinical trial with an investigational product. Registries and observational studies are allowed. * Mental inability, reluctance, or language difficulties of the subject, in the opinion of the investigator, that result in difficulty in understanding the meaning of participation in the trial.